secwatch / observer
CMPX Compass Therapeutics, Inc.
CIK 0001738021 49 ready 8-Ks latest August 6, 2026, 7:30 AM ET RSS · JSON
Activity: NORMAL 1 filings / 30d vs 1 baseline
Ready 8-Ks 49
Latest filing August 6, 2026, 7:30 AM ET
Top materiality 0.85
Event mix other_material ×18 · leadership ×12 · earnings ×11
Sentiment 15 pos · 2 neg · 32 neu
Executive change recent →

Recent 8-K filings for CMPX

Highest-materiality recent filing

Compass Therapeutics reports tovecimig Phase 2/3 BTC data with significant PFS benefit; BLA planned

May 5, 2026, 7:59 PM ET other material materiality 0.85 positive item 2.02item 9.01 ◈ Earnings Releases

Read filing →

Executive changes

Role change

Thomas Schuetz

President and Chief Executive Officer
CMPX · Compass Therapeutics, Inc.
Effective
2024-05-28
Filed
May 28, 2024, 7:59 PM ET
On May 28, 2024, the Board of Directors appointed Thomas Schuetz, MD, PhD, then-current President of Research and Development and Vice Chair of the Board of Directors of the Company, as President and Chief Executive Officer of the Company, and as Principal Executive Officer, Principal Financial and Principal Accounting Officer of the Company, effective immediately.
Departed

Vered Bisker-Leib

Chief Executive Officer
CMPX · Compass Therapeutics, Inc.
Effective
2024-05-28
Successor
Thomas Schuetz
Filed
May 28, 2024, 7:59 PM ET
On May 28, 2024, Vered Bisker-Leib, PhD, MBA, resigned as Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer) and resigned as a member of the Board of Directors, of Compass Therapeutics, Inc. (the “Company”) effective the same date.
Role change

Vered Bisker-Leib

Chief Executive Officer
CMPX · Compass Therapeutics, Inc.
Effective
2024-01-09
Filed
January 9, 2024, 6:59 PM ET
the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”) appointed Vered Bisker-Leib, PhD as Chief Executive Officer of the Company and a member the Board, each effective January 9, 2024.
Role change

Thomas Schuetz

President of Research and Development
CMPX · Compass Therapeutics, Inc.
Effective
2024-01-09
Successor
Vered Bisker-Leib
Filed
January 9, 2024, 6:59 PM ET
Effective January 9, 2024, Thomas Schuetz, MD, PhD, the Company’s Scientific Founder and Chief Executive Officer and a member of the Board, will transition to President of Research and Development and be appointed Vice Chair of the Board.
Appointed

Richard S. Lindahl

Class III Director
CMPX · Compass Therapeutics, Inc.
Effective
2023-04-21
Filed
April 24, 2023, 7:59 PM ET
On April 21, 2023, the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”) approved the appointment of a new director to its Board: Richard S. Lindahl, MBA, who is currently the executive vice president, chief financial officer, and treasurer of Emergent BioSolutions, Inc.
Departed

David Wurzer

Director
CMPX · Compass Therapeutics, Inc.
Effective
2023-02-20
Filed
February 24, 2023, 6:59 PM ET
On February 20, 2023, David Wurzer, a member of the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board, and all committees thereof, for personal family reasons effective immediately.
Appointed

David Wurzer

Director
CMPX · Compass Therapeutics, Inc.
Effective
2023-02-08
Filed
February 10, 2023, 6:59 PM ET
On February 8, 2023, the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”) approved the appointment of a new director to its Board: David Wurzer, CPA, CFO of Enko Chem, Inc.
Departed

Susan Kalled, PhD

Chief Scientific Officer
CMPX · Compass Therapeutics, Inc.
Effective
2022-11-29
Filed
November 29, 2022, 6:59 PM ET
On November 29, 2022, Susan Kalled, PhD departed her position as Chief Scientific Officer of Compass Therapeutics, Inc.
Appointed

James P. Boylan

Director
CMPX · Compass Therapeutics, Inc.
Filed
November 2, 2022, 7:59 PM ET
On November 1, 2022, the Board appointed Mr. Boylan to join as a director of the Board, effective upon the closing of the Private Placement.
Departed

Stephen Squinto

Director
CMPX · Compass Therapeutics, Inc.
Effective
2022-08-31
Filed
August 19, 2022, 7:59 PM ET
On August 17, 2022, Stephen Squinto, Ph.D., a member of the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board and all committees thereof, effective August 31, 2022.
Departed

Miranda Toledano

Director
CMPX · Compass Therapeutics, Inc.
Effective
2022-05-24
Filed
April 26, 2022, 7:59 PM ET
On April 22, 2022, Miranda Toledano, M.B.A., a member of the Board of the Company, notified the Company that she is declining to stand for reelection to the Board at the completion of her current term, ending at the Company’s Annual Meeting of Stockholders set for May 24, 2022.
Appointed

Ellen Chiniara

Director
CMPX · Compass Therapeutics, Inc.
Effective
2022-04-25
Filed
April 26, 2022, 7:59 PM ET
On April 25, 2022, the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”) appointed two new directors to its Board: Ellen Chiniara, J.D., former Chief Legal Officer of Alexion Pharmaceuticals; and Mary Ann Gray, Ph.D., President of Gray Strategic Advisors.

Materiality & sentiment trend

Max materiality 0.85 · Median 0.65 · Most common event other_material

15 positive 2 negative 32 neutral

source · CMPX on sec.gov